别名 ANKTM1、ankyrin-like with transmembrane domains 1、Ankyrin-like with transmembrane domains protein 1 + [7] |
简介 Receptor-activated non-selective cation channel involved in pain detection and possibly also in cold perception, oxygen concentration perception, cough, itch, and inner ear function (PubMed:21873995, PubMed:23199233, PubMed:25389312, PubMed:25855297). Shows 8-fold preference for divalent over monovalent cations (PubMed:31447178). Has a central role in the pain response to endogenous inflammatory mediators and to a diverse array of irritants, such as allylthiocyanate (AITC) from mustard oil or wasabi, cinnamaldehyde, diallyl disulfide (DADS) from garlic, and acrolein, an irritant from tears gas and vehicle exhaust fumes (PubMed:25389312, PubMed:27241698, PubMed:30878828, PubMed:20547126). Acts also as an ionotropic cannabinoid receptor by being activated by delta(9)-tetrahydrocannabinol (THC), the psychoactive component of marijuana (PubMed:25389312). Is activated by a large variety of structurally unrelated electrophilic and non-electrophilic chemical compounds. Electrophilic ligands activate TRPA1 by interacting with critical N-terminal Cys residues in a covalent manner, whereas mechanisms of non-electrophilic ligands are not well determined. May be a component for the mechanosensitive transduction channel of hair cells in inner ear, thereby participating in the perception of sounds. Probably operated by a phosphatidylinositol second messenger system (By similarity). |
作用机制 TRPA1激动剂 [+1] |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2008-02-20 |
作用机制 COX抑制剂 [+3] |
在研适应症- |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 英国 |
首次获批日期1998-08-06 |
作用机制 TRPA1抑制剂 [+2] |
在研适应症- |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期1986-01-20 |
开始日期2024-11-01 |
申办/合作机构 Yale University [+1] |
开始日期2024-09-01 |
申办/合作机构 Yale University [+1] |
开始日期2024-06-15 |